MedTrace Logo

R-2487 in Patients With Rheumatoid Arthritis

NCT05961592 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2025-09-23

No results posted yet for this study

Summary

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis.

Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

R-2487 DP

Probiotic

Sponsors & Collaborators

  • Rise Therapeutics LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-19
Primary Completion
2026-11-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961592 on ClinicalTrials.gov